Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Immune Complex Detection Service
Are you currently facing complex challenges in predicting biotherapeutic immunogenicity or mitigating the risk of serious hypersensitivity reactions? Our NHP Immune Complex Detection Service helps you proactively assess and manage these critical risks, ensuring patient safety and a smoother path to clinical trials. Through our advanced bioanalytical strategies and deep toxicological expertise, we provide the clear, actionable data you need to make informed decisions and accelerate your drug development journey.
Overview of NHP Immune Complex Detection Service
Immunogenicity—the development of anti-drug antibodies (ADAs)—is a significant risk in the development of biotherapeutics. While ADAs can alter a drug's pharmacokinetics and efficacy, their most severe consequence is the formation of circulating immune complexes (ICs), which can trigger fatal hypersensitivity reactions. Non-human primates (NHPs) serve as a crucial preclinical model for detecting and characterizing these reactions due to their close genetic and immunological similarities to humans. Our service leverages these similarities to provide a predictive safety assessment before your compound reaches the clinic.
What Our Service Is
Our NHP Immune Complex Detection Service is a comprehensive bioanalytical solution designed to identify, characterize, and quantify immune complexes in NHP serum or plasma samples. This service specifically detects complexes formed by the binding of anti-drug antibodies (ADAs) to biotherapeutics and evaluates complement system activation, a key factor associated with immune complex–mediated adverse events. It is particularly valuable for immunogenicity risk mitigation, enabling a better understanding of the relationship between ADA formation and immune complex development, and supporting the design of safer therapeutic molecules and dosing strategies.
Why Choose Us?
The value we create for our clients is the ability to transform a critical pain point—the unpredictability of immunogenicity—into a clear and manageable aspect of drug development. We help you move beyond simply confirming the presence of ADAs to understanding their functional impact. Our service provides the detailed, high-quality data that regulatory agencies demand, enabling you to build a robust safety package and expedite your program.
Key Benefits of Our Service
Creative Biolabs' approach to IC detection is defined by precision, speed, and scientific depth. We offer a holistic solution that goes beyond basic screening to provide a complete picture of your biotherapeutic's immunogenic profile.
- Access to Extensive NHP Resources: Our partnerships with accredited NHP research centers provide access to well-characterized cynomolgus macaques and rhesus monkeys, ensuring the use of a reliable and translationally relevant model.
- Customization and Method Development: Each biotherapeutic is unique. We develop and validate custom assays tailored to your specific molecule, ensuring optimal sensitivity and specificity for your program. This includes the ability to overcome drug tolerance issues and target interference.
- In-Depth Reporting and Expert Consultation: You receive more than just raw data. Our final reports include detailed analysis and expert interpretation from our team of bioanalytical and toxicological specialists, providing valuable insights into the clinical and histopathological implications of your findings.
How Creative Biolabs' Services Can Assist Your Project?
Our service provides clear, actionable insights into your biotherapeutic's safety profile, helping you anticipate and solve potential immunogenicity challenges before they escalate. We deliver the definitive data required for confident decision-making and regulatory success.
01
Required Starting Materials
02
Consultation and Assay Design
03
Sample Receipt and Pre-treatment
04
Bioanalytical Testing and Detection
05
Characterization and Quantification
06
Data Analysis and Expert Review
Key Deliverables
Upon completion of your project, you will receive a comprehensive package designed for regulatory submission and internal decision-making.
- Detailed laboratory report
- Raw and processed data files
- Comprehensive data analysis report integrating bioanalytical and clinical findings
- Expert consultation and final presentation of results
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: How do you handle the challenges of low drug tolerance in my samples?
A: We understand that high drug concentrations can interfere with IC detection. We address this challenge with specialized pre-treatment methods and our validated assays are optimized to be highly drug-tolerant. Our scientists work with you to ensure our methods are robust enough to handle your specific samples and provide accurate results.
Q: Can your service differentiate between different types of immune complexes?
A: Yes. While a basic screen confirms the presence of ICs, we offer a tiered approach that includes characterization assays like Size Exclusion Chromatography (SEC)-ELISA. This allows us to separate and analyze ICs based on their size and composition, providing deeper insights into their potential to cause adverse reactions.
Q: Is the immunogenicity data from NHPs truly predictive of human responses?
A: While NHP immunogenicity is not always perfectly predictive of the human response, it is the most relevant animal model for assessing the potential for immune-related adverse events. Our service helps you identify "red flags" early in development, allowing you to implement risk mitigation strategies and design clinical trials with enhanced safety monitoring.
Q: My project has a tight timeline. Can your service be accelerated?
A: We are committed to meeting our clients' timelines. Our streamlined processes and dedicated project management ensure we can deliver quality data efficiently. For urgent projects, please discuss your specific needs with our team during the initial consultation, and we will do our best to accommodate your schedule.
Contact Us
Creative Biolabs is dedicated to providing the scientific excellence and strategic partnership you need to succeed. Our NHP Immune Complex Detection Service is a testament to our commitment to advancing safe and effective biotherapeutics. For more information and to discuss how our services can be tailored to your specific project needs, please reach out to our team of experts today.